NovaBay: Tomorrow's Staple In Antimicrobial Therapy?
By Timeless Wealth:NovaBay Pharmaceuticals (NBY) is developing products that represent a microcosm of the Johnson & Johnsons, Strykers and Medtronics of the world -- non-discretionary healthcare items that will always be in demand, particularly given the swelling global population. NVC-422 is an antimicrobial, but not an antibiotic. It's a development-stage drug that mimics the mechanism of action of human white blood cells. It's being developed in ophthalmology in eye drop form to treat viral conjunctivitis; in urology to reduce the incidence of urinary catheter blockage and encrustation, as well as associated urinary tract infections; and as a gel to treat impetigo, a contagious skin infection.NVC-422, which NovaBay dubbed an "Aganocide" compound, answers a fundamental need for anti-infectives that do not give rise to bacterial resistance. Incidences with widely prescribed antibiotics failing to work as intended have risen exponentially in the last few decades. An article published by Forbes six years agoComplete Story »